Technique and results for integration of the quest MPS all-blood cardioplegia delivery unit for modified ultrafiltration.
All blood cardioplegia delivery units offer the advantage of removing additional crystalloid volumes associated with multidose crystalloid or 4:1 blood cardioplegia. Further reductions in crystalloid and prime volumes can be achieved if the cardioplegia delivery unit can be integrated as the modified ultrafiltration (MUF) unit as well. This article reports our technique and results for integration of the Quest MPS all-blood cardioplegia delivery unit (Quest Medical, Allen, TX) for modified ultrafiltration. The charts of 50 consecutive patients were reviewed. Patient age ranged from 3 days to 5 years. There were nine neonates. Patient weight ranged from 1.7 to 20.4 kg. Standard prime volumes were 400 cc for patients weighing less than 12 kg, and 800 cc for patients weighing more than 12 kg. Cardiopulmonary bypass time ranged from 32 to 231 minutes. All patients were perfused with corporeal temperatures above 31 degrees C except Norwood cases. MUF time ranged from 5 to 15 minutes with an average of 10.2 minutes. Volume removed ranged from 100 to 600 cc with an average of 239 cc. There was one mortality (2%), which was unrelated to MUF. Additional prime volume was not required to initiate MUF through the MPS cardioplegia unit. The Quest MPS all-blood CPG unit can be safely and effectively integrated as a MUF unit without additional prime volumes. This approach allows for mild hypothermic cardiopulmonary bypass, multidose all-blood CPG, and MUF to be used with tremendous limitation of crystalloid usage.
Gates
Richard N
RN
Department of Cardiac Surgery, Children's Hospital of Orange County, Orange, CA, USA.
Parker
Beth
B
D002315:Cardiopulmonary Bypass / Q000295:instrumentation* / Q000379:methods*; D002675:Child, Preschool; D006324:Heart Arrest, Induced / Q000295:instrumentation*; D006440:Hemofiltration / Q000295:instrumentation* / Q000379:methods*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016896:Treatment Outcome